IXICO Plc (LSE:IXI) has upgraded its Revenue guidance, more than doubled its share count in a £10m fundraise and signed a technology collaboration with Medidata, yet its shares still trade at around 8p, close to the 52-week low of 6.625p set in May 2026 and roughly the April placing price. For a London-listed neuroscience imaging specialist now expecting at least £8.0m of revenue in the year to 30 September 2026, that combination is worth examining.

The key question is whether IXICO's "TechBio" pivot, licensing its AI-driven IXI platform to partners rather than relying solely on contract research work, can convert a strengthening order book into a sustainably profitable business. The next data point will be the FY26 full-year results.

July trading update: FY26 revenue guidance raised to at least £8.0m

On 7 July 2026 IXICO said revenue for the year ending 30 September 2026 is now expected to be at least £8.0m, roughly 22% ahead of FY25's £6.5m and above the previous market forecast of £7.5m. Chief executive Bram Goorden attributed the upgrade to "a continued uplift in contract wins, contract extensions, and revenue diversification", adding that the results show "the fruits of that strategy as it matures".

On 13 July 2026 came a more nuanced Huntington's disease (HD) update. Two HD programmes had been discontinued by their sponsors since the half-year results, removing about £1.5m from the order book across the next two financial years. IXICO stressed that £8.0m of new HD awards had been secured in the first half of FY26, that the order book remained 21% above the FY25 year-end level, and that "programme descoping is always a sad moment for the medical community, it is a normal feature of clinical drug development". The board confirmed that FY26 and FY27 revenue guidance were unchanged and that it "continues to expect the Company to meet or exceed market expectations".

The pairing shows both the resilience of IXICO's HD Franchise and why management is diversifying into Alzheimer's disease (AD) and Parkinson's disease (PD), where the addressable market is far larger.

What IXICO does

London-headquartered IXICO operates as an imaging contract research organisation (iCRO): biopharma sponsors running neurological drug trials send MRI and PET scans to IXICO, whose proprietary AI-driven IXI platform standardises collection, checks eligibility and safety criteria, and quantifies imaging biomarkers such as amyloid burden or brain-volume change. The company says it has analysed hundreds of thousands of scans across AD, HD, PD, multiple sclerosis and rarer neurological conditions.

Revenue comes mainly from multi-year contracts tied to individual trials, so the order book (£18.1m at 31 March 2026) is the key forward indicator. Under its TechBio strategy, IXICO is adding two higher-margin channels: licensing the IXI platform to CROs and electronic data capture providers, and pursuing FDA approval of the platform as software as a medical device (SaMD) for clinical decision support. The non-exclusive Medidata collaboration announced on 26 March 2026, integrating IXI with the Dassault Systèmes-owned trials platform, is the first tangible step.

Biomarker work has also given IXICO a foothold in diagnostics. Its amyloid PET analysis supported the June 2025 FDA clearance of Fujirebio's Lumipulse blood test for Alzheimer's pathology, and on 21 May 2026 it won a contract, worth £1.3m over two years alongside an HD Phase 2 extension, to validate another AD blood-based biomarker for an unnamed global diagnostics company.

Half-year results: revenue up 23%, losses narrowing at the EBITDA line

Interim results for the six months to 31 March 2026, published on 19 May 2026, showed revenue of £3.9m, up 23% from £3.2m a year earlier, with gross Margin improving to 53.2% from 49.6%. The EBITDA loss narrowed to £0.5m from £0.7m. Lower down, the reported operating loss widened to £1.6m from £0.9m and the loss before tax to £1.588m from £0.889m, with basic loss per share of 1.21p against 1.11p. Management attributed much of this to the reclassification of R&D tax credits and impairments; the adjusted operating loss improved to £0.778m from £0.998m.

Cash stood at just £1.7m at 31 March 2026, down from £5.0m a year earlier, but before the fundraise. IXICO raised £10m gross (£9.4m net) at 8p per share through two placings and a directors' subscription, with a small retail offer alongside; the second placing completed on 27 April 2026 once HMRC advance assurance under the EIS/VCT rules arrived. Octopus Investments and Gresham House took most of the shares, and the share count rose to 218.0m.

For the year to 30 September 2025, revenue was £6.5m (up 13%), gross margin 48.7%, the EBITDA loss £1.3m (FY24: £1.7m) and the loss before tax £2.4m. There is no dividend. Management's stated ambition is £10m of revenue in the medium term and £20m-plus longer term.

What could drive the stock next?

The FY26 results, expected around December, will show whether the "at least £8.0m" guidance is met or beaten and how the £10m raised is being deployed: £6m was earmarked for platform integration and automation, £2m for the partner sales strategy and £2m for FDA SaMD work.

Commercial evidence from the Medidata collaboration, or further platform-licensing deals, would validate the TechBio thesis; management argued in March that such a model could justify enterprise valuations of four to seven times revenue against one to three times for typical CROs, though that is a management view, not an independent assessment. Additional AD and PD contract wins, order-book growth beyond £18.1m and any SaMD regulatory milestone are the other catalysts, with the shift towards blood-based Alzheimer's diagnostics, which still need PET imaging analysis for validation, a broader tailwind.

Risks investors should watch

IXICO remains loss-making, and the £10m raise came at a heavy cost in dilution, with the share count more than doubling. If the TechBio Investment does not generate revenue quickly, further Capital could be needed. Reported losses widened at the half-year stage despite revenue growth, so the adjusted figures deserve scrutiny.

Concentration is a structural risk: the July update showed how sponsor decisions to discontinue HD programmes can strip £1.5m from the order book at short notice. Biopharma budgets remain cautious, a point management flagged in December 2025. The licensing and SaMD strategies are unproven and depend on partners, regulators and lengthy validation cycles. With a Market Value of only around £17m at 8p, Liquidity is thin and the shares can move sharply on modest volumes.

Outlook

IXICO enters the final quarter of FY26 with upgraded guidance, a funded Balance Sheet and an order book covering most of the year's expected revenue. A share price near the placing level and the 52-week low suggests the market wants proof that the TechBio strategy can turn growth into profit rather than simply absorbing fresh capital. The FY26 results, order-book disclosures, traction from Medidata and evidence that reported losses are reversing will decide whether 2026 proves an overlooked story or another year of investment.